6 days Ago By ABMN Staff
Hemostemix Inc. ( CVE:HEM – Get Free Report )’s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$0.
12 and traded as low as C$0.09. Hemostemix shares last traded at C$0.
09, with a volume of 2,500 shares. Hemostemix Trading Down 5.3 % The company has a quick ratio of 0.
48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
The stock’s fifty day moving average price is C$0.12 and its two-hundred day moving average price is C$0.13.
The company has a market capitalization of C$13.12 million, a PE ratio of -2.62 and a beta of 0.
20. Insiders Place Their Bets In related news, Director Peter Alan Lacey acquired 200,000 shares of Hemostemix stock in a transaction that occurred on Thursday, March 6th. The stock was bought at an average price of C$0.
15 per share, with a total value of C$30,000.00. 10.
43% of the stock is currently owned by company insiders. Hemostemix Company Profile Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter ..
